Alzheimer’s: this pill from the Viagra family could slow cognitive decline by 31%, but the results call for caution

Alzheimer's: this pill from the Viagra family could slow cognitive decline by 31%, but the results call for caution
Could a pill a day slow the progression of Alzheimer’s disease? The drug AR1001 showed encouraging results in some patients with an early form of the disease, with a 31% slowing of clinical decline. But this figure, apparently very promising, concerns only a portion of patients.

For families facing Alzheimer’s, each scientific advance nourishes legitimate hope. We still need to understand what these results really allow us to hope for.

31% less decline: a result that concerns some patients

For families facing Alzheimer’s, each new therapeutic avenue represents hope. It is in this context that the results of AR1001, a drug developed by the South Korean company AriBio, have attracted attention.

Presented on November 17, 2026 at the international Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston, they come from the phase 3 POLARIS-AD trial. This brought together 1,535 people with an early form of the diseasein 13 countries, for 52 weeks.

Participants received 30 mg of AR1001 or a placebo daily. The researchers notably measured the evolution of their cognitive abilities and their autonomy using the CDR-SB score, a scale which assesses the consequences of the disease on memory, orientation and daily activities.

But the figure of 31% deserves essential clarification. It only concerns the 604 participants who were not taking, at the start of the study, either an acetylcholinesterase inhibitor or memantine, two treatments used in Alzheimer’s. In this group, AR1001 slowed clinical decline by 31% compared to placebo. The difference was statistically significant (p = 0.0266).

On the other hand, in all 1,535 participants, the observed slowdown was only 7% and was not statistically significant (p = 0.4015).

In other words, the effectiveness of the drug has not been demonstrated in the entire population studied. A fundamental nuance to avoid transforming a targeted result into a general promise.

A molecule from the Viagra family, but developed against Alzheimer’s

Another particularity of AR1001: it belongs to the family of phosphodiesterase type 5 (PDE5) inhibitors, like Viagra, used against erectile dysfunction.

This pharmacological proximity has given rise to comparisons. But AR1001 is a molecule specifically developed to study its potential against Alzheimer’s. You should therefore definitely not consider taking Viagra to prevent or slow down Alzheimer’s.

Its mechanism of action is based in particular on the modulation of cyclic GMP, a molecule involved in different cellular processes. Researchers are thus seeking to act on mechanisms likely to participate in brain functioning and the progression of the disease.

Analyzes of cerebrospinal fluid, which surrounds the brain and spinal cord, showed increased levels of cyclic GMP in treated participants. A favorable change in another biomarker, phosphorylated tau protein p-tau217, was also observed in the monotherapy group.

These results provide interesting biological elements, without demonstrating that the drug lastingly modifies all of the mechanisms of the disease.

Richard Oakley, deputy director of research and innovation at the Alzheimer’s Society, was optimistic to Euronews: “These preliminary results are a very promising sign, because they show that we may have a completely new treatment for early forms of Alzheimer’s disease that addresses its causes and not just its symptoms.”.

Overall moderate side effects, according to the laboratory

Tolerance constitutes another major issue for patients. According to data communicated by Fosun Pharma, adverse effects were reported in 69% of participants on AR1001, compared to 66.4% on placebo. Serious adverse events were comparable: 10% versus 9.8%.

The most common side effects with AR1001 were diarrhea (7.7%), falls (7.3%), and dizziness (6.1%). The majority were mild to moderate in intensity.

Another element to take into account: 88% of participants completed the 52 weeks of double-blind treatment. Of those eligible who completed this first phase, more than 95% chose to continue in an extension of the study, during which all participants receive AR1001.

These initial data are rather reassuring, but they will need to be examined in detail based on the full results of the trial, particularly regarding longer-term tolerance.

For families, nothing changes for the moment

Despite these results, AR1001 remains an experimental drug. It is not authorized for prescription in France and the detailed data from POLARIS-AD have not yet been the subject of a complete peer-reviewed scientific publication. AriBio now plans to discuss these results with the Food and Drug Administration (FDA), the American drug authority.

In the meantime, care is still based on early diagnosis, coordinated medical monitoring, maintaining autonomy and support for loved ones.

AR1001 opens an additional avenue in research against Alzheimer’s, but not yet a new therapeutic solution. For families waiting for treatments capable of slowing the disease, the signal observed in 604 patients is encouraging. However, it remains to be confirmed by full analysis of the data and their independent evaluation.

In an illness that disrupts the lives of patients and their loved ones, hope is precious. But it must be based on sufficiently solid evidence to one day become a real medical breakthrough.